Literature DB >> 16007415

Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C?

Ritesh Agarwal, Dheeraj Gupta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16007415     DOI： 10.1007/s00134-005-2723-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  7 in total

1.  Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity.

Authors:  O Lider; Y A Mekori; T Miller; R Bar-Tana; I Vlodavsky; E Baharav; I R Cohen; Y Naparstek
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

2.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

3.  Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma.

Authors:  M A Fath; X Wu; R E Hileman; R J Linhardt; M A Kashem; R M Nelson; C D Wright; W M Abraham
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

4.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

5.  The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis.

Authors:  Y Matzner; G Marx; R Drexler; A Eldor
Journal:  Thromb Haemost       Date:  1984-10-31       Impact factor: 5.249

6.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Authors:  Edward Abraham; Konrad Reinhart; Steven Opal; Ignace Demeyer; Christopher Doig; Angel López Rodriguez; Richard Beale; Petr Svoboda; Pierre Francois Laterre; Stuart Simon; Bruce Light; Herbert Spapen; Judy Stone; Allan Seibert; Claus Peckelsen; Cathy De Deyne; Russell Postier; Ville Pettilä; Charles L Sprung; Antonio Artigas; Sandra R Percell; Vincent Shu; Christian Zwingelstein; Jeffrey Tobias; Lona Poole; James C Stolzenbach; Abla A Creasey
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

7.  Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions.

Authors:  H P Ekre; B Fjellner; O Hägermark
Journal:  Int J Immunopharmacol       Date:  1986
  7 in total
  1 in total

Review 1.  Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis.

Authors:  Changsong Wang; Chunjie Chi; Lei Guo; Xiaoyang Wang; Libo Guo; Jiaxiao Sun; Bo Sun; Shanshan Liu; Xuenan Chang; Enyou Li
Journal:  Crit Care       Date:  2014-10-16       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.